Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | KCNC1 | P48547 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16806276 | 0.76 | MAOB (0.34) | CCR1CCR5CCR8KCNC1CYP1A2 | |
| SCHEMBL16806272 | 0.72 | KDM4E (0.41) | CYP1A2CYP1B1 | |
| SCHEMBL16806279 | 0.71 | KCNC1 (0.33) | KCNC1 | |
| SCHEMBL8738219 | 0.69 | CCR1 (0.31) | CCR1CCR5CCR8 | |
| SCHEMBL16806275 | 0.69 | CCR1 (0.41) | CCR1CCR5CCR8KCNC1 | |
| SCHEMBL4750515 | 0.68 | CYP1A2 (0.43) | CCR1CCR5CCR8CYP1A2CYP1B1 | |
| SCHEMBL16806281 | 0.68 | CYP1A2 (0.30) | CYP1A2CYP1B1 | |
| SCHEMBL21970011 | 0.64 | CCR1 (0.30) | CCR1CCR5CCR8 | |
| SCHEMBL16806278 | 0.63 | ALDH1A1 (0.36) | CYP1A2CYP1B1 | |
| SCHEMBL16576791 | 0.63 | CYP3A4 (0.45) | CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CCR1 4266/4885CCR5 4238/4885CCR8 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.